BLSM
- Analyst Upgrades
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners maintains BlossomHill Therapeutics with a Outperform and raises the price target from $36 to $40. ...
- Analyst Upgrades
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics with a Buy and raises the price target from $30 to $40. ...
- GlobeNewswire
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN ...
- GlobeNewswire
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no ...
- GlobeNewswire
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative ...
- Analyst Upgrades
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
LifeSci Capital initiates coverage on BlossomHill Therapeutics with a Outperform rating and announces Price Target of $32. ...
- Analyst Upgrades
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36
Leerink Partners initiates coverage on BlossomHill Therapeutics with a Outperform rating and announces Price Target of $36. ...
- Analyst Upgrades
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics with a Overweight rating and announces Price Target of $28. ...
- Analyst Upgrades
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics with a Buy rating and announces Price Target of $30. ...
- GlobeNewswire
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by ...
- Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35
HC Wainwright & Co. analyst Robert Burns initiates coverage on BlossomHill Therapeutics with a Buy rating and announces Price Target of $35. ...
- GlobeNewswire
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative ...
- GlobeNewswire
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to ...